Gurejeet al. BMC Health Services Research (2015) 15:242
DOI 10.1186/s12913-015-0911-3
Investigación original / Original research
Rev Panam Salud Publica 35(1), 2014
STATUTORY INSTRUMENTS | SUPPLEMENT No. 8 28th March, 2014 | STATUTORY INSTRUMENTS SUPPLEMENT | to The Uganda Gazette No. 18 Volume CVII dated 28th March, 2014 | Printed by UPPC, Entebbe, by Order of the Government. | STATUTORY INSTRUMENTS | 2014 No. 29.
(Health Systems in Transition, Vol. 4, No. 3, 2014)
This document, Ghana’s National Newborn Health Strategy and Action Plan 2014–2018 outlines a targeted strategy for accelerating the reduction of newborn deaths in Ghana. Furthermore it provides a costed action plan with clearly marked timelines for implementation to facilitate resource mobilisat...ion, monitoring and evaluation, and scaling up of proposed newborn interventions. It is expected that all stakeholders working towards improving the health of children in Ghana will buy into this plan and collaborate towards attainment of the goals and objectives outlined here.
more
Introduction
Chapter A.10
A Training Curriculum for Providers
Summary of key informant interviews with representatives of organizations providing, funding, or supporting WASH services to refugee populations
Indian Journal of Psychiatry 56(3), Jul‐Sep 2014; DOI: 10.4103/0019-5545.140615
Best Practices Report.PART 1 Primary Protection: Enhancing Health Care Resilience for a Changing Climatei Primary Protection: EnhancingU.S. Department of Health and Human Services
Clinical guideline, Methods, Evidence and Recommendations
In this guideline the following is covered: information needs of people with chronic hep
titis B and their carers; where children, young people and adults with chronic hepatitis B a-
should be assessed; assessment of liver disease, includi...ng the use of non-invasive tests and genotype testing; criteria for offering antiviral treatment; the efficacy, safety and cost effectiveness of currently available treatments; selection of first-line therapy; management of treatment failure or drug resistance; prophylactic treatment during im-
munosuppressive therapy; and monitoring for treatment response
more